Impact of MYCN status on response of high-risk neuroblastoma to neoadjuvant chemotherapy
Yanishevski D, McCarville M, Doubrovin M, Spiegl H, Zhao X, Lu Z, Federico S, Furman W, Murphy A, Davidoff A. Impact of MYCN status on response of high-risk neuroblastoma to neoadjuvant chemotherapy. Journal Of Pediatric Surgery 2019, 55: 130-134. PMID: 31685267, DOI: 10.1016/j.jpedsurg.2019.09.067.Peer-Reviewed Original ResearchConceptsNon-amplified tumorsNeoadjuvant chemotherapyHigh-risk neuroblastomaCurie scoreTumor responseMYCN amplificationGreater mean percentage reductionHigh-risk neuroblastoma patientsMetastatic disease responsePrimary tumor responsePercentage of patientsPrimary tumor volumeAggressive clinical phenotypeMean percentage reductionPercentage volume changeLocoregional diseaseSurgical resectionMetastatic sitesNeuroblastoma patientsPrimary tumorTumor resectionTumor volumeCT scanMYCN statusChemotherapy